We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+26.71%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$624M
AUM Growth
+$131M
Cap. Flow
+$40.1M
Cap. Flow %
6.42%
Top 10 Hldgs %
81.94%
Holding
58
New
13
Increased
11
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
MOBI
Mobia Medical
MOBI
+$10.3M
2
SENS icon
Senseonics Holdings Inc
SENS
+$10.3M
3
CGON icon
CG Oncology
CGON
+$7.19M
4
ELVN icon
Enliven Therapeutics
ELVN
+$6.37M
5
JBIO
Jade Biosciences
JBIO
+$6.26M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$8.33M
2
VIR icon
Vir Biotechnology
VIR
+$4.1M
3
MDT icon
Medtronic
MDT
+$2.42M
4
CNC icon
Centene
CNC
+$2.29M
5
NTRA icon
Natera
NTRA
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Consumer Staples 0.17%
3 Consumer Discretionary 0.09%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2026 Portfolio in Review

As of Q2 2026, Avidity Partners Management held 58 positions worth $624M, up 26% from $494M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Avidity Partners Management deployed $40.1M of net new capital in Q2 2026, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Mobia Medical: 798,282 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $8.33M trimmed.

  • Avidity Partners Management's largest Q2 2026 buy was Mobia Medical: 798,282 shares worth $10.7M.
  • Avidity Partners Management added most to CG Oncology in Q2 2026, an estimated $7.19M increase.
  • Avidity Partners Management's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $8.33M.
  • Avidity Partners Management fully exited Centene in Q2 2026, selling an estimated $2.29M.
  • Avidity Partners Management's ten largest holdings make up 82% of its $624M portfolio in Q2 2026.
  • Avidity Partners Management opened 13 new positions and closed 13 in Q2 2026.
  • Avidity Partners Management's portfolio value rose 26% quarter-over-quarter to $624M.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.